On October 4, Eton Pharmaceuticals, Inc. announced it entered into an agreement to acquire an abbreviated new drug application for Nitisinone Capsules from Oakrum Pharma, LLC. This transaction is part of Oakrum Pharma’s Chapter 11 bankruptcy proceedings.
Nitisinone Capsules were approved by the FDA in May 2023 for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.
Oakrum Pharma is a biopharmaceutical company focusing on development and commercialization of affordable drug therapies
Eton Pharmaceuticals is an innovative pharmaceutical company focused on developing, acquiring and commercializing products to address unmet needs in patients suffering from rare diseases. For the quarter ended March 31, 2023, the company reported net revenues of $5.3 million.
Eton expects to launch the product in the first quarter of 2024 and plans to offer its Eton Cares support program to all patients. The financial terms of the acquisition were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 86th Pharmaceutical acquisition of the year.
